International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 957-963 , 15 March 2001

The impact of irregularly rising prostate-specific antigen and “impending failure” on the apparent outcome of localized prostate cancer following radiotherapy

  • David C Hodgson, M.D. (M.P.H.)

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests to: Dr. David Hodgson, Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Canada M6G 2M9
    • ,
  • Charles N Catton, M.D.

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Padraig Warde (M.B.)

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Mary K Gospodarowicz, M.D.

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Michael F Milosevic, M.D.

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Michael McLean M.B

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Pamela Catton, M.D. (M.A.)

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

,Accepted 5 September 2000.

References 

  1. Goad JR, Chang SJ, Ohori M, et al.  PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am. 1993;20:727–736
  2. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer (Followup). J Urol. 1993;149:519–522
  3. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate (New insights into outcome from repeat biopsy and prostate specific antigen followup). J Urol. 1994;152:1806–1812
  4. Lee WR, Hanks GE, Schultheiss TE, et al.  Localized prostate cancer treated by external-beam radiotherapy alone (Serum prostate-specific antigen-driven outcome analysis). J Clin Oncol. 1995;13(2):464–469
  5. American Society for Therapeutic Radiology, and Oncology Consensus Panel . Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37(5):1035–1041
  6. D’Amico AV, Whittington R, Malkowicz SB, et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974
  7. Zelefsky MJ, Wallner KE, Ling CC, et al.  Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517–522
  8. Shipley WU, Thames HD, Sandler HM, et al.  Radiation therapy for clinically localized prostate cancer (A multi-institutional pooled analysis). JAMA. 1999;281:1598–1604
  9. Horwitz EM, Vicini FA, Ziaja EL, et al.  The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 1998;41:267–272
  10. Ennis RD, Malyszko BK, Heitjan DF, et al.  Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:511–517
  11. Zietman AL, Coen JJ, Dallow KC, et al.  The treatment of prostate cancer by conventional radiation therapy. An analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995;32(2):287–292
  12. Blasko JC, Wallner K, Grimm PD, et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995;154:1096–1099
  13. Pilepich MV, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using goserelin in unfavorable- prognosis carcinoma of the prostate treated with definitive radiotherapy. Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013–1021
  14. Pilepich MV, Krall JM, al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma (A randomized comparative trial of the Radiation Therapy Oncology Group). Urology. 1995;45:616–623
  15. Horwitz EM, Vicini FA, Ziaja EL, et al.  Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 1996;36:565–571
  16. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer (Prognostic implications). Int J Radiat Oncol Biol Phys. 1994;30:279–287
  17. Zietman AL, Tibbs MK, Dallow KC, et al.  Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1–2 adenocarcinoma of the prostate. Radiother Oncol. 1996;40(2):159–162
  18. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radaition therapy for clinically localized prostate cancer (The relationship between nadir level and disease-free survival). J Urol. 1996;156(2 Pt 1):450–453
  19. Kestin LL, Vicini FA, Ziaja EL, et al.  Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer. 1999;86(8):1557–1566
  20. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 1994;152(5 Pt 2):1786–1791
  21. Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer. 2000;88:2305–2318
  22. Pickles T, Duncan GG, Kim-sing C, et al.  PSA relapse definitions—The Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys. 1999;43:699–700
  23. Hanks GE, Hanlon AL, Pinover WH, et al.  Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 1999;5(3):152–158
  24. Hanks GE, Hanlon AL, Schultheiss TE, et al.  Dose escalation with 3D conformal treatment (Five year outcomes, treatment optimization, and future directions). Int J Radiat Oncol Biol Phys. 1998;41(3):501–510
  25. Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 2000;46:559–566
  26. Hanks GE, Hanlon AL, Schultheiss TE, et al.  Dose escalation with 3D conformal treatment (five year outcomes, treatment optimization, and future directions). Int J Radiat Oncol Biol Phys. 1998;41:501–510
  27. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  28. Pollack A, Zagars GK, Smith LG, et al.  Preliminary results of a randomized does-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer (Abstr). Int J Radiat Oncol Biol Phys. 1999;45:146
  29. Lu J. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer. Semin Urol Oncol. 2000;18:83–92

☆ Dr. Hodgson is supported by an Adam Linton Fellowship from the Ontario Medical Association.

PII: S0360-3016(00)01431-0

doi: 10.1016/S0360-3016(00)01431-0

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 957-963 , 15 March 2001

Article Tools

* Image Usage & Resolution